Literature DB >> 17303367

Depression is associated with worse patency and recurrent leg symptoms after lower extremity revascularization.

Gregory S Cherr1, Jiping Wang, Pamela M Zimmerman, Hasan H Dosluoglu.   

Abstract

OBJECTIVES: Depression is associated with worse outcomes after coronary artery bypass surgery, but its association with the results after revascularization for symptomatic peripheral arterial disease (PAD) is unknown. This study assessed the association between depression and patency, recurrent symptoms, and limb salvage after revascularization for symptomatic PAD.
METHODS: Electronic medical records were retrospectively reviewed for all patients with symptomatic PAD who underwent intervention (open, endovascular, or combined) between January 2000 and October 2004. All patients were previously screened for depression, and treatment was initiated as indicated by the primary care physician or psychiatrist. Demographic data and outcomes were recorded using published guidelines. Outcomes of interest included primary patency of the revascularization (bypass graft or angioplasty/stented artery), assisted primary patency, secondary patency, recurrent symptomatic ipsilateral PAD, and major amputation. Follow-up was available for all patients (mean, 23.4 +/- 14.1 months).
RESULTS: Board-certified vascular surgeons performed all interventions. At the time of intervention, 78 (36.1%) of 216 patients had been diagnosed with depression. Compared with those without depression, depressed patients were younger (64.4 vs 69.1 years; P = .001), currently using tobacco (74.4% vs 51.4%; P = .001), and less likely to have hypertension (79.5% vs 89.9%; P = .03). No other significant differences were noted for cardiovascular risk factors or prevalent comorbidities. During follow-up, 50 patients (23.1%) had failing or failed revascularizations, and 24 (11%) had amputations. Those with depression at the time of the PAD intervention, compared at 24 months with patients without depression, had significantly worse primary patency (58.2% vs 79.8%; P = .02), primary assisted patency (59.5% vs 81.5%; P = .01), and secondary patency (60.2% vs 82.2%; P = .007). They also had a significantly increased risk of recurrent symptomatic PAD (33.7% vs 20.8%; P = .03) but not major amputation (13.8% vs 10.4%; P = .73). By multivariate analysis, patients with depression were at significantly increased risk for recurrent symptomatic PAD (hazard ratio [HR], 1.77; 95% confidence interval [CI], 1.03 to 3.02; P = .04) and failure of revascularization (HR, 2.18; 95% CI, 1.22 to 3.88; P < .01), but not major amputation.
CONCLUSIONS: Depression is common among patients undergoing intervention for symptomatic PAD. After intervention, patients with depression have worse outcomes for the affected leg. Prospective analysis is required to confirm these results.

Entities:  

Mesh:

Year:  2007        PMID: 17303367     DOI: 10.1016/j.jvs.2006.11.057

Source DB:  PubMed          Journal:  J Vasc Surg        ISSN: 0741-5214            Impact factor:   4.268


  15 in total

Review 1.  The impact of vascular burden on late-life depression.

Authors:  Micaela Santos; Enikö Kövari; Patrick R Hof; Gabriel Gold; Constantin Bouras; Panteleimon Giannakopoulos
Journal:  Brain Res Rev       Date:  2009-09-08

2.  Depression and incident diabetic foot ulcers: a prospective cohort study.

Authors:  Lisa H Williams; Carolyn M Rutter; Wayne J Katon; Gayle E Reiber; Paul Ciechanowski; Susan R Heckbert; Elizabeth H B Lin; Evette J Ludman; Malia M Oliver; Bessie A Young; Michael Von Korff
Journal:  Am J Med       Date:  2010-08       Impact factor: 4.965

3.  Prognostic differences for functional recovery after major lower limb amputation: effects of the timing and type of inpatient rehabilitation services in the Veterans Health Administration.

Authors:  Margaret G Stineman; Pui L Kwong; Dawei Xie; Jibby E Kurichi; Diane Cowper Ripley; David M Brooks; Douglas E Bidelspach; Barbara E Bates
Journal:  PM R       Date:  2010-04       Impact factor: 2.298

Review 4.  Screening and Management of Depression in Patients With Cardiovascular Disease: JACC State-of-the-Art Review.

Authors:  Manish K Jha; Arman Qamar; Muthiah Vaduganathan; Dennis S Charney; James W Murrough
Journal:  J Am Coll Cardiol       Date:  2019-04-16       Impact factor: 24.094

5.  Depression and incident lower limb amputations in veterans with diabetes.

Authors:  Lisa H Williams; Donald R Miller; Graeme Fincke; Jean-Philippe Lafrance; Ruth Etzioni; Charles Maynard; Gregory J Raugi; Gayle E Reiber
Journal:  J Diabetes Complications       Date:  2010-08-30       Impact factor: 2.852

6.  Patients with depression are at increased risk for secondary cardiovascular events after lower extremity revascularization.

Authors:  Gregory S Cherr; Pamela M Zimmerman; Jiping Wang; Hasan H Dosluoglu
Journal:  J Gen Intern Med       Date:  2008-02-26       Impact factor: 5.128

7.  The association of comorbid depression with mortality and amputation in veterans with peripheral artery disease.

Authors:  Shipra Arya; Sujin Lee; Greg J Zahner; Beth E Cohen; Jade Hiramoto; Owen M Wolkowitz; Anjali Khakharia; Zachary O Binney; S Marlene Grenon
Journal:  J Vasc Surg       Date:  2018-03-24       Impact factor: 4.268

Review 8.  Exercise training and peripheral arterial disease.

Authors:  Tara L Haas; Pamela G Lloyd; Hsiao-Tung Yang; Ronald L Terjung
Journal:  Compr Physiol       Date:  2012-10       Impact factor: 9.090

9.  Association between depression and peripheral artery disease: insights from the heart and soul study.

Authors:  S Marlene Grenon; Jade Hiramoto; Kim G Smolderen; Eric Vittinghoff; Mary A Whooley; Beth E Cohen
Journal:  J Am Heart Assoc       Date:  2012-08-24       Impact factor: 5.501

10.  Comparison of quality of life in patients with peripheral arterial disease caused by atherosclerosis obliterans or Buerger's disease.

Authors:  Rojbin Karakoyun; Cüneyt Köksoy; Zeynep Şener; Umut Gündüz; Baris Karakaş; Mustafa Karakoyun
Journal:  Cardiovasc J Afr       Date:  2014 May-Jun       Impact factor: 1.167

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.